Market Place
Sourcing Support
OBI Pharma Announces Ph 1/2 Study Initiation for OBI-992, a TROP2-Targeted ADC
12 Jun 2024 //
GLOBENEWSWIRE
OBI Pharma Announces Poster Presentations at the AACR 2024 Annual Meeting
18 Mar 2024 //
GLOBENEWSWIRE
OBI Pharma Announces FDA Clearance of IND Application for a Phase 1/2 of OBI-992
08 Jan 2024 //
PR NEWSWIRE
OBI Pharma Announces Clearance of IND for a Phase 1/2 Study of OBI-992
03 Jan 2024 //
GLOBENEWSWIRE
OBI Pharma Appoints Heidi Wang, Ph.D. as Chief Executive Officer
02 Jun 2023 //
GLOBENEWSWIRE
OBI Pharma Announces Poster Presentations at AACR 2023 Meeting for OBI-999
10 Apr 2023 //
GLOBENEWSWIRE
OBI Pharma Announces Discontinuation of PI/II Study of its Antibody- OBI 888
05 Jul 2022 //
GLOBENEWSWIRE
OBI Pharma Announces Poster Presentations at the 2022 ASCO
17 May 2022 //
GLOBENEWSWIRE
OBI Pharma Announces Poster Presentations at AACR 2022
07 Apr 2022 //
PRNEWSWIRE
Biosion Licenses BSI04702, to OBI for WW Development & Commercialization Rights
11 Dec 2021 //
PRNEWSWIRE
OBI Pharma Announces First Patient Enrolled on SWOG Cancer Research OBI-3424
26 Apr 2021 //
PRNEWSWIRE
OBI Pharma Announces First Patient Enrolled on SWOG Network`s OBI-3424
26 Apr 2021 //
PRNEWSWIRE
OBI Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424
06 Apr 2021 //
PRNEWSWIRE
OBI Pharma Announces Poster at 2020 ASCO Adagloxad Simolenin, OBI-999,OBI-3424
20 May 2020 //
PRNEWSWIRE
OBI Pharma Updates on Clinical Trial Activities During COVID-19 Pandemic
08 Apr 2020 //
PRNEWSWIRE
OBI Announces Poster Presentations at AACR 2021 Annual Meeting for OBI-3424
05 Apr 2020 //
PRNEWSWIRE
OBI Pharma Granted FDA Orphan Drug Designation for Treatment of Gastric Cancer
21 Jan 2020 //
PR NEWSWIRE
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.